Tourmaline Bio Reports $23.1 Million Net Loss in Q2 2025, Driven by Increased R&D Expenses

Tourmaline Bio, Inc. reported a net loss of $23.1 million for the second quarter of 2025, compared to a net loss of $17.5 million for the same period in 2024, reflecting an increase of 32.1%. For the first half of 2025, the company recorded a net loss of $46.1 million, up from $30.8 million in the prior year. The increase in losses is attributed primarily to heightened research and development expenses, which rose to $19.6 million in Q2 2025 from $15.7 million in Q2 2024, driven by costs associated with ongoing clinical trials for its lead product candidate, pacibekitug.

Total operating expenses for the second quarter of 2025 were $26.0 million, up from $22.0 million in the same quarter of 2024. The increase was largely due to a $3.0 million rise in clinical trial expenses related to the TRANQUILITY and spiriTED trials, alongside increased payroll-related costs. General and administrative expenses remained relatively stable, increasing slightly to $6.3 million from $6.2 million year-over-year. The company’s cash, cash equivalents, and investments totaled $256.4 million as of June 30, 2025, providing a runway to fund operations into the second half of 2027.

In terms of strategic developments, Tourmaline Bio completed a reverse merger with Talaris Therapeutics in October 2023, which allowed it to transition into a publicly traded entity. The merger was accompanied by a significant capital raise of approximately $75 million through a private placement prior to the merger. The company is focused on advancing pacibekitug, a monoclonal antibody targeting interleukin-6, with ongoing clinical trials aimed at treating cardiovascular inflammation and thyroid eye disease. The Phase 2 TRANQUILITY trial has shown promising results, achieving significant reductions in high-sensitivity C-reactive protein levels, a key inflammatory marker.

Operationally, Tourmaline Bio has expanded its clinical focus, recently nominating abdominal aortic aneurysm as an additional indication for pacibekitug. The company is also preparing to initiate a Phase 2 proof-of-concept trial for this indication in the latter half of 2025. As of June 30, 2025, the company had 25.7 million shares outstanding, reflecting a slight increase from the previous quarter, and continues to evaluate additional opportunities for in-licensing and acquisitions to enhance its product pipeline.

Looking ahead, Tourmaline Bio anticipates continued increases in research and development expenditures as it progresses through clinical trials and prepares for potential commercialization of pacibekitug. The company remains focused on securing additional funding through equity or debt financing, collaborations, and licensing arrangements to support its operational and developmental needs. The management has indicated that while the current cash position is sufficient for the near term, future capital requirements will depend on the outcomes of ongoing clinical trials and the overall market conditions.